Sheng Wang, PhD, is a renowned molecular biologist and pharmacologist with expertise in structural-based drug design. He received his Doctor of Philosophy (PhD) in Molecular and Cell Biology from the University of Chinese Academy of Sciences. Currently, he serves as a Professor at the Center for Excellence in Molecular Cell Science at the Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences. Dr. Wang has made significant contributions to the field through his research on G protein-coupled receptors (GPCRs) and small molecule regulators for signaling pathways.
Author Metrics:
Google Scholar Profile
Dr. Wang’s publications have garnered significant attention and citations within the scientific community. His research articles have been published in top-tier journals such as Cell, Nature, Science, and PNAS. The impact of his work is evidenced by his high citation count and the recognition of his papers as cover stories in prestigious journals.
Citations: Dr. Wang’s research has been cited 3,591 times, indicating a significant impact within the scientific community. Citations reflect the extent to which other researchers have referenced Dr. Wang’s work in their own studies, suggesting its importance and relevance to the field.
h-index: Dr. Wang’s h-index is 16, which means that he has published at least 16 papers that have each received at least 16 citations. The h-index provides a measure of both the productivity and impact of a researcher’s publications.
i10-index: Dr. Wang’s i10-index is 17, indicating that he has published at least 17 papers that have each received at least 10 citations. This index is particularly useful for measuring the productivity and impact of recent publications, as it focuses on the number of papers with a minimum of 10 citations.
Education:
Wang completed his Bachelor of Science (minor) at Wuhan University and a Bachelor of Science in Food Quality and Safety at Huazhong Agricultural University. He earned his PhD in Molecular and Cell Biology from the University of Chinese Academy of Sciences, focusing on molecular and cell biology, with a specialization in structural-based drug design.
Research Focus:
Dr. Wang’s research primarily revolves around structural-based drug design and understanding the molecular mechanisms of GPCR pharmacology and signaling. He has also contributed significantly to the discovery of small molecule regulators for key signaling pathways, such as the Wnt/β-catenin pathway. His work has implications for developing novel therapeutics for various diseases, including psychiatric disorders and cancer.
Professional Journey:
After completing his PhD, Dr. Wang pursued postdoctoral research at the University of North Carolina at Chapel Hill, where he investigated the structural basis of GPCR pharmacology and signaling. He later joined the Center for Excellence in Molecular Cell Science at the Chinese Academy of Sciences as a Principal Investigator, focusing on structural-based drug design.
Honors & Awards:
Dr. Wang has received recognition for his contributions to the field of molecular biology and pharmacology. His work has been acknowledged with honors and awards from prestigious institutions and professional societies. These accolades highlight his outstanding achievements and impact in the scientific community.
Publications Noted & Contributions:
Wang’s publications have made significant contributions to advancing our understanding of molecular pharmacology and drug design. Notable contributions include elucidating the structural basis of receptor activation, discovering novel small molecule regulators for signaling pathways, and developing new therapeutic strategies for psychiatric disorders and cancer.
Recognition of methamphetamine and other amines by trace amine receptor TAAR1
- Authors: H Liu, Y Zheng, Y Wang, X He, P Xu, S Huang, Q Yuan, X Zhang, …
- Journal: Nature
- Volume/Issue: 1-3, 8, 2023
2-Phenylcyclopropylmethylamine Derivatives as Dopamine D2 Receptor Partial Agonists: Design, Synthesis, and Biological Evaluation
- Authors: W Yan, L Fan, J Yu, R Liu, H Wang, L Tan, S Wang, J Cheng
- Journal: Journal of medicinal chemistry
- Volume/Issue: 64 (23), 17239-17258, 2021
Serotonin 2A Receptor (5-HT2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants
- Authors: W Duan, D Cao, S Wang, J Cheng
- Journal: Chemical Reviews
- Volume/Issue: 4, 2023
Transformation of a Dopamine D2 Receptor Agonist to Partial Agonists as Novel Antipsychotic Agents
- Authors: R Liu, J Qi, H Wang, L Fan, P Zhang, J Yu, L Tan, S Wang, J Cheng
- Journal: Journal of Medicinal Chemistry
- Volume/Issue: 66 (9), 6274-6287, 2023
Advances in structure-based drug design: The potential for precision therapeutics in psychiatric disorders
- Authors: D Cao, P Zhang, S Wang
- Journal: Neuron
- Volume/Issue: 1, 2024
Research Timeline:
Wang’s research journey has been marked by significant milestones and achievements. Starting from his graduate studies, through his postdoctoral research, to his current position as a Principal Investigator, he has consistently made impactful contributions to the field of molecular biology and pharmacology. His research timeline showcases a progression of expertise and innovation in structural-based drug design.
Collaborations and Projects:
Dr. Wang has been involved in collaborative projects with leading researchers and institutions worldwide. These collaborations have facilitated interdisciplinary research and the exchange of ideas, leading to groundbreaking discoveries in molecular pharmacology and drug design. Wang’s involvement in collaborative projects underscores the importance of teamwork and knowledge sharing in advancing scientific research.
